Gland Pharma share price: Revenue from operations fell 10% year-on-year to Rs 1,384 crore. EBITDA increased by 1% year-on-year to Rs 360 crore, with margins improving by 300 basis points to 26%. R&D expenses were Rs 43.7 crore, making up 4.3% of the revenue.
Dalal Street Week Ahead: Sideways consolidation likely to persist amid global trade uncertainty
The Nifty experienced a week of range-bound trading, closing slightly lower with a 0.53% loss. Facing resistance near the upper edge of a rising channel,
July 26, 2025